Mr. Thiyagalingam currently serves as Chief Executive Officer of PainTEQ, a disruptive technology serving patients suffering from sacroiliac joint dysfunction and supporting the interventional pain market. From 2020 through 2025, he held successive leadership roles at the company—from Chief Commercial Officer to Chief Operating Officer, and ultimately as CEO. During his tenure, he led the company’s transformation from early-stage startup to hyper-growth innovator in the interventional pain space. He also led M&A initiatives and was instrumental in securing a Category 1 CPT code for the LinQ procedure—a new therapy in the interventional pain market. Under his leadership, PainTEQ was recognized three years in a row by the INC 5000 and named a “Best Place to Work” by the Tampa Bay Business Journal. Prior to this he worked in senior leadership roles across reputable companies such as Abbott, Nevro and Stryker. He holds a Bachelor of Medical Science from the University of Sydney, a master’s in marketing management, and an MBA from Macquarie Graduate School of Management (MGSM). He is also a certified Gallup Strengths Coach and is passionate about fostering high-performance cultures and mentoring emerging leaders in the medtech industry.
